TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22460183
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and azathioprine (3 intravenous pulses of methylprednisolone 1 g at months 1, 3, and 5; oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for 6 months, followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further 6 months)
Study: 11417034
Drug: Prepackaged antimalarial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prepackaged antimalarial drugs
Study: 8275216
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention consisting of a diet with 28% of calories as total fat (< 8% saturated fat, up to 9% polyunsaturated fat, 11% monounsaturated fat) and dietary cholesterol intake less than 75 mg/1000 kcal (< 150 mg/d)
Study: 8225624
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (2.2 g)
Study: 20839290
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg subcutaneous injections every 6 months for 3 years)
Study: 3307888
Drug: Grenz rays
Normalized name: Ray Dol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grenz rays in a total dose of 900 rad (9 Gy) given in three equal doses at 21‐day intervals
Study: 26060122
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg prasugrel loading dose (LD) followed by an additional 30 mg prasugrel at the time of PCI
Study: 3908435
Drug: oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acyclovir 200 mg five times daily for five days
Study: 19655244
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation at 50,000 IU weekly for 12 weeks
Study: 20670096
Drug: Intranasal estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal estradiol (300 μg/day estradiol hemihydrate)
Study: 25933183
Drug: DTwP-HepB+Hib vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP-HepB+Hib vaccine (Pentavac)
Study: 30170781
Drug: Multi-strain probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-strain probiotics (Ecologic®Barrier) 2.5 × 10^9 cfu/g, twice daily for 6 months
Study: 16763405
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with chemotherapy including anthracycline
Study: 11736878
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (AmB) administered at 1 mg kg(‐1) day(‐1) in lipid emulsion (doseform=2)
Study: 31972580
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy (71% of patients received this intervention)
Study: 16670692
Drug: Imedeen Prime
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imedeen Prime Renewal (two tablets twice daily for 6 months)
Study: 3597568
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy intervention (approximately six sessions within 3-5 months of bereavement)
Study: 8712425
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) bolus injection of meperidine 0.6 mg/kg and ketorolac 0.5 mg/kg
Study: 19164205
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg
Study: 9537487
Drug: Separate injection
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injection of DTaP and candidate Hib vaccine
Study: 7012968
Drug: Intermittent tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent tetracycline therapy
Study: 21368772
Drug: Anthrax Vaccine
Normalized name: ANTHRAX VACCINE
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthrax Vaccine Adsorbed (AVA)
Study: 30628950
Drug: Hydrocortisone continuous
Normalized name: HYDROCORTISONE 10 mg in 1 g TOPICAL AEROSOL, SPRAY [Hydrocortisone Continuous]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone continuous infusion (200 mg/d)
Study: 9756554
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 6 g daily for 3 days
Study: 22894911
Drug: Rapeseed oil
Normalized name: Rapeseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed oil diet enriched with α-linolenic acid (ALA) (3.5 g/d)
Study: 2060564
Drug: Caffeine 12
Normalized name: caffeine 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 12 mg.kg‐1.day‐1
Study: 27180442
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream loaded with 2% Ananas comosus extract
Study: 12476540
Drug: Flunisolide HFA
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide HFA (all doses)
Study: 8169675
Drug: Intravenous slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous slow infusion of indomethacin
Study: 29120039
Drug: Prostin 15M
Normalized name: Prostin VR
DrugBank: Carboprost tromethamine (DB00429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostin 15M 250 microg intramuscular injection every two hours until 1 cm cervical dilation, then every three hours until abortion.
Study: 16234005
Drug: Wireless capsule
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless capsule endoscopy (WCE)
Study: 28085022
Drug: Whole-grain (WG)
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain (WG) foods (80 g/day)
Study: 25752438
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg VIA-2291 for 24 weeks
Study: 2575521
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg (P40)
Study: 27496798
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment
Study: 8233289
Drug: IVIG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG treatment
Study: 29093246
Drug: Lumbrokinase in
Normalized name: lumbrokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbrokinase in combination with low molecular heparin and sequential warfarin (n=30)
Study: 21670447
Drug: Palifermin 120
Normalized name: palifermin
DrugBank: Palifermin (DB00039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palifermin 120 μg/kg
Study: 16478746
Drug: Weekly darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly darbepoetin alfa
Study: 2946313
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of fentanyl
Study: 2946313
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of alfentanil
Study: 10830451
Drug: Hypo-osmolar ORS
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypo-osmolar ORS (224 mmol/L)
Study: 18466210
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump treatment
Study: 12830340
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg o.d.
Study: 30874716
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (n=1096)
Study: 29953782
Drug: Intraperitoneal combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal combined with intravenous neoadjuvant chemotherapy
Study: 26035186
Drug: Vortioxetine 15
Normalized name: vortioxetine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 15 mg
Study: 21606533
Drug: Patients carrying
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients carrying CC(rs12979860)
Study: 12192323
Drug: Specialized amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized amino acid mixture (14 g arginine, 3 g HMB, 14 g glutamine)
Study: 820365
Drug: Podophyllin treatment
Normalized name: podophyllin
DrugBank: Podophyllin (DB09094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Podophyllin treatment for simple plantar warts
Study: 16543072
Drug: Filgrastim 5
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim 5 microg/kg daily starting on day 1 posttransplant
Study: 1604908
Drug: Sodium monofluorophosphate
Normalized name: Sodium Monofluorophosphate
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium monofluorophosphate (MFP) tablets for 7 days
Study: 14759641
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg twice daily
Study: 8546884
Drug: Hyperhydrated subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperhydrated subjects (0.1 g sodium chloride (NaCl)/kg body wt and 26 mL water/kg body wt)
Study: 25246664
Drug: Low-dose mannitol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mannitol control
Study: 22818224
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole 1mg/kg every 12 hours
Study: 19880686
Drug: Armodafinil, 150
Normalized name: Armodafinil, 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil, 150 mg
Study: 25774646
Drug: Postcard intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postcard intervention (9 postcards over 12 months plus usual treatment)
Study: 21120518
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 3 mg kg(‐1)
Study: 15000637
Drug: Saturated potassium
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saturated potassium nitrate/dimethyl isosorbide in aqueous hydroxyethyl cellulose gel
Study: 11723147
Drug: Low-carbohydrate meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate meal (25 g)
Study: 25987072
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride injection before anesthesia induction (Control Group)
Study: 29659672
Drug: ADI-PEG 20
Normalized name: ADI-PEG 20
DrugBank: Pegargiminase (DB06592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADI-PEG 20 18 mg/m2
Study: 15967567
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg propiverine twice daily
Study: 15967567
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tolterodine twice daily
Study: 10386467
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of 240 mg polyestradiol phosphate (PEP) every second week for the first 8 weeks, followed by a maintenance dose of 240 mg every month
Study: 19506392
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (1.3, 2.0, and 2.7 mg/m(2)/day)
Study: 15730347
Drug: Nefazodone 200
Normalized name: NEFAZODONE 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 200 mg twice daily (n = 34)
Study: 14607207
Drug: Candesartan cilexetil,
Normalized name: Candesartan Cilexetil, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan cilexetil, 8 mg once daily
Study: 1873204
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy (8-methoxypsoralen)
Study: 15741723
Drug: Sucrose solution
Normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose solution
Study: 28315479
Drug: personalized pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: personalized pharmaceutical and psychological education
Study: 20704667
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with parameters: wavelength 905 nm, frequency 5,000 Hz, power density of 12 mW/cm², dose of 2 J/cm², treatment time 120 seconds, total dose 12 J/cm²
Study: 15565373
Drug: Glibenclamide +
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glibenclamide + Metformin
Study: 22832261
Drug: Intradermal low-antigen-content
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal low-antigen-content split inactivated vaccine
Study: 19582577
Drug: Patient self-administered
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-administered abdominal pressure
Study: 7649582
Drug: Human amylin
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human amylin infusion
Study: 8988940
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol intake (492 mg/d)
Study: 27941394
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 300 mg b.i.d.
Study: 2904474
Drug: acetazolamide 750
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetazolamide 750 mg per os
Study: 18494791
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day TPM
Study: 12353197
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg (13.9‐27.0 mg/kg) twice daily
Study: 26432182
Drug: 675 mg
Normalized name: arginine 675 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 675 mg TEV-48125
Study: 21672926
Drug: One extra
Normalized name: Acid Gone Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: One extra daily injection of rLH
Study: 8695243
Drug: Serum beta
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum beta HCG > or = 4 IU/l (multivariate analysis)
Study: 23441598
Drug: Sevoflurane combined
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane combined with propofol and 8 mg of ondansetron
Study: 23441598
Drug: Sevoflurane and
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane and 8 mg of ondansetron
Study: 23441598
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and 8 mg of ondansetron
Study: 2966193
Drug: Low-dose adrenaline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adrenaline infusion
Study: 22828645
Drug: MenC-TT booster
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenC-TT booster dose
Study: 12900588
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg (up-titrated to 100 mg if needed)
Study: 9888118
Drug: Weekly contingent
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly contingent condition
Study: 2006660
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with a combination of triamterene and hydrochlorothiazide
Study: 8934993
Drug: Combination IAN
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination IAN block and mock PDL injections (needle penetration only)
Study: 22805174
Drug: Continuous Treatment
Normalized name: Continuously Clear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Treatment (CT)
Study: 29328639
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (0.2 mL of 0.8% gel)
Study: 10450387
Drug: One-step hydrogen
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step hydrogen peroxide and multipurpose solutions
Study: 24672936
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received inotropic agents, preload and afterload reducing therapy, anti-infection, etc.
Study: 2979673
Drug: Pirenzepine 150
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 150 mg
Study: 6829485
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Zn daily supplement (group B)
Study: 11340315
Drug: Foot Reflex
Normalized name: Cuscuta reflexa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot Reflex Zone Massage (FRZM) therapy
Study: 26704611
Drug: Suppressive acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suppressive acyclovir therapy
Study: 2360135
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Cefotetan 0.5 g, Cefotetan 1.0 g, Ceftriaxone 0.25 g)
Study: 695661
Drug: Prophylactic gestagen
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic gestagen therapy
Study: 695661
Drug: Prophylactic gestagen
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic gestagen therapy initiated at the first missed period or later
Study: 15049437
Drug: Augmentan film-coated
Normalized name: clavulanate
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Augmentan film-coated tablet (875/125)
Study: 21862415
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate (1.4 mg/m²) administered as a 2- to 5-minute intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
Study: 24148807
Drug: Active conservative
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active conservative treatment (pelvic floor muscle training and bladder training)
Study: 22362830
Drug: Brief Mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Mobile Treatment (BMT)
Study: 9822507
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone (6 mg every 12 hours for a total of 4 doses)
Study: 8126916
Drug: Intra-arterial infusions
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusions of epirubicin (Group B)
Study: 30365356
Drug: Low-dose iron
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iron sucrose (0 to 400 mg monthly)
Study: 1290178
Drug: A/S 3
Normalized name: Amoxicillin/Sulbactam 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/S 3 x 3 g for 3 days (Part II)
Study: 11934682
Drug: Low-dose IGF-I
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IGF-I therapy (40 microg.kg(‐1).day(‐1))
Study: 19487635
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin infusion at 2.0 units/h
Study: 31525168
Drug: Protein Supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein Supplementation (PRO; 28.7 g casein protein)
Study: 17646509
Drug: Dexamethasone 16
Normalized name: dexamethasone 16 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 16 mg IV
Study: 21384392
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser treatments on one side of the body three times per week for 2 weeks
Study: 27503012
Drug: Telmisartan combined
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan combined with clopidogrel (50 mg/d)
Study: 7248480
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination of 80 mg propranolol twice daily and 2.5 mg bendrofluazide twice daily
Study: 7248480
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination (Inderetic) of 80 mg propranolol twice daily and 2.5 mg bendrofluazide twice daily
Study: 21054769
Drug: 10/25 mg
Normalized name: Vaseretic 10/25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/25 mg amlodipine/HCTZ